Clinical Trial Update: Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating early in-hospital initiation of inclisiran for acute coronary syndrome to assess efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Coronary Syndrome | Phase 3 | Status: RECRUITING